SHPH Fundamental Analysis - SHUTTLE PHARMACEUTICALS HOLD

Fundamental Rating

Overall SHPH gets a fundamental rating of 1 out of 10. We evaluated SHPH against 547 industry peers in the Biotechnology industry. SHPH may be in some trouble as it scores bad on both profitability and health. SHPH is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SHPH has reported negative net income.

SHPH had a negative operating cash flow in the past year.

SHPH had negative earnings in each of the past 5 years.

In the past 5 years SHPH always reported negative operating cash flow.

1.2 Ratios

SHPH's Return On Assets of -220.59% is on the low side compared to the rest of the industry. SHPH is outperformed by 90.16% of its industry peers.

SHPH's Return On Equity of -336.77% is on the low side compared to the rest of the industry. SHPH is outperformed by 72.68% of its industry peers.

		Industry Rank	Sector Rank
ROA	-220.59%
ROE	-336.77%
ROIC	N/A

ROA(3y)-170.32%

ROA(5y)-174.67%

ROE(3y)-496.91%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SHPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SHPH has more shares outstanding than it did 1 year ago.

Compared to 1 year ago, SHPH has a worse debt to assets ratio.

2.2 Solvency

SHPH has an Altman-Z score of -15.60. This is a bad value and indicates that SHPH is not financially healthy and even has some risk of bankruptcy.

SHPH has a worse Altman-Z score (-15.60) than 79.78% of its industry peers.

SHPH has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.

SHPH has a Debt to Equity ratio of 0.12. This is in the lower half of the industry: SHPH underperforms 64.85% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Altman-Z	-15.6

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.07 indicates that SHPH has no problem at all paying its short term obligations.

SHPH has a Current ratio of 3.07. This is in the lower half of the industry: SHPH underperforms 63.21% of its industry peers.

A Quick Ratio of 3.07 indicates that SHPH has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.07, SHPH is doing worse than 60.47% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.07
Quick Ratio	3.07

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SHPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.87%, which is quite good.

EPS 1Y (TTM)9.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%86.36%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SHPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SHPH!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SHUTTLE PHARMACEUTICALS HOLD

NASDAQ:SHPH (8/22/2025, 8:00:02 PM)

After market: 3.46 +0.02 (+0.62%)

3.4388

+0.06 (+1.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2022-11-14/bmo

Earnings (Next)N/A N/A

Inst Owners0.84%

Inst Owner Change-98%

Ins Owners5.31%

Ins Owner Change0%

Market Cap3.68M

AnalystsN/A

Price TargetN/A

Short Float %1.96%

Short Ratio0.02

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.02
P/tB	1.02
EV/EBITDA	N/A

EPS(TTM)-64.49

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-9.88

FCFYN/A

OCF(TTM)-9.88

OCFYN/A

SpS0

BVpS3.37

TBVpS3.37

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-220.59%
ROE	-336.77%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-170.32%

ROA(5y)-174.67%

ROE(3y)-496.91%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.07
Quick Ratio	3.07
Altman-Z	-15.6

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)9.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%86.36%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-30.61%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-124.43%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-124.43%

OCF growth 3YN/A

OCF growth 5YN/A

SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens